Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: A family of compounds effective in suppressing lymphocyte activation is comprised of 7-(oxoalkyl)1,3-dialkyl xanthines, other than denbufylline, of the formula in which R1 and R2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group.

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

Abstract: Disclosed are methods for treating conditions resulting from hyperoxia or mechanical ventilation comprising the administration of a compound of the formula: ##STR1## wherein R.sub.1 is a substantially pure resolved R enantiomer .omega.-1, secondary alcohol-substituted (C.sub.5-8) alkyl; and R.sub.2 and R.sub.3 are independently hydrogen atom or a (C.sub.1-12) alkyl optionally containing one or two oxygen atoms in place of non-adjacent carbon atoms.

Abstract: There is disclosed a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans by administering an effective amount of a compound that inhibits cellular signaling through a specific phospholipid-based cellular signaling and signal amplification pathway. The invention further provides a method for preventing or delaying clinical symptoms of a group of viral diseases wherein the viral disease is mediated by host cell viral replication. The invention provides an advantage by attacking host cellular signaling mechanisms to prevent the development of drug resistance from rapidly mutating viruses.

Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and

Abstract: In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.

Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and

Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).

Abstract: There is disclosed a method for screening for inhibitors of cellular second messenger signaling regulated by lysophosphatidic acid acyl transferase (LPAAT) and phosphatidic acid phosphohydrolase (PAPH), which method comprises contacting target cells or appropriate subcullular elements under appropriate conditions of stimulation with a candidate drug and assessing the levels of the relevant subsets of phosphatidic acid (PA) and diacylglycerol (DAG) in the presence and absence of the candidate drug.

Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and

Abstract: There is disclosed a method for reversing the multiple drug resistant (MDR) phenotype in tumors insensitive to hydrophobic chemotherapeutic drugs due to over expression of mdr-1, comprising administering an effective amount of a long chain amino alcohol compound. There is further disclosed a method for preventing the development of MDR during cancer chemotherapy treatments, comprising administering during cancer chemotherapy treatments an effective amount of a long chain amino alcohol compound.

Abstract: The specification discloses methods for modulating cellular metabolism in a subject, modulating being desirable to mitigate a condition of the subject. Disclosed methods include processes for administering to said subject an effective amount of a compound of the formula ##STR1## wherein one and only one of R.sup.1 and R.sup.3 is a straight-chain or branched-chain .omega.-hydroxyalkyl (5-8C), or is a branched-chain (.omega.-1)-hydroxyalkyl (5-8C), or is an (.omega.-1)-oxoalkyl (5-8C), or is an (.omega., .omega.-1) or (.omega.-1, .omega.-2)-dihydroxyalkyl (5-8C), or is an alkenyl substituent (5-8C), and the other is alkyl (1-12C) optionally containing one or two non-adjacent oxygen atoms in place of C.